CeriBell (NASDAQ:CBLL) CEO Sells $54,975.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 2,199 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $25.00, for a total value of $54,975.00. Following the sale, the chief executive officer owned 819,214 shares in the company, valued at $20,480,350. The trade was a 0.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Xingjuan Chao also recently made the following trade(s):

• On Wednesday, August 19th, Xingjuan Chao sold 31,415 shares of CeriBell stock. The shares were sold at an average price of $25.03, for a total value of $786,317.45.
• On Tuesday, July 7th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $19.90, for a total transaction of $776,100.00.
• On Monday, June 8th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.33, for a total transaction of $714,870.00.

CeriBell Trading Down 0.5%

Shares of NASDAQ CBLL opened at $24.20 on Friday. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $25.33. The company has a 50-day moving average of $19.54 and a two-hundred day moving average of $19.22. The company has a market cap of $928.80 million, a PE ratio of -13.75 and a beta of 0.81. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The company had revenue of $28.10 million for the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. As a group, equities analysts expect that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CBLL has been the subject of several research reports. Canaccord Genuity Group lifted their target price on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Barclays raised CeriBell to a “neutral” rating in a research note on Tuesday. BTIG Research raised their price target on CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Finally, Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.40.

More CeriBell News

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Analyst price targets increased. BTIG Research raised its target from $28 to $30 and reiterated a Buy rating, while Canaccord Genuity lifted its target from $25 to $26 and also maintained a Buy rating. These revisions indicate continued confidence in CeriBell’s growth prospects. CeriBell Stock Price Expected to Rise, BTIG Research Analyst Says
• Positive Sentiment: Institutional interest has been supportive. TimesSquare Capital Management initiated a position valued at approximately $15.2 million, while KCM Capital increased its holdings by 40% to 1.4 million shares. Additional firms also established or expanded positions, suggesting some professional investors see value in CBLL.
• Neutral Sentiment: Recent financial results were mixed. CeriBell’s quarterly revenue of $28.1 million exceeded the $27.28 million consensus estimate, but its $0.51 per-share loss was wider than the expected $0.47 loss. The company remains unprofitable, and analysts expect a full-year loss of approximately $1.96 per share.
• Neutral Sentiment: Analyst opinion remains generally favorable but valuation expectations are uneven. The consensus rating is “Moderate Buy,” although the average target of $22.40 is below the recent trading level. Barclays upgraded the stock to Neutral, reflecting a more cautious stance.
• Negative Sentiment: Senior executives sold a substantial number of shares. CEO Xingjuan Chao sold 33,614 shares for about $841,000 across August 18–19, reducing her holdings by roughly 4%. CFO Scott Blumberg sold 34,502 shares for approximately $864,000, cutting his direct ownership by about 18.45%. The transactions occurred around $25 per share, close to CeriBell’s 52-week high, and could be interpreted as profit-taking or a potential near-term confidence signal. CeriBell Insider Trading Activity

Institutional Investors Weigh In On CeriBell

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Strs Ohio acquired a new position in shares of CeriBell during the 1st quarter worth about $27,000. Caitong International Asset Management Co. Ltd increased its stake in shares of CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after acquiring an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of CeriBell in the 3rd quarter valued at approximately $33,000. CWM LLC boosted its stake in CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after acquiring an additional 1,697 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after acquiring an additional 1,801 shares during the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.